Related Experiment Video
Updated: Jan 24, 2026

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
Published on: May 18, 2020
Beta blockade as adjunctive breast cancer therapy: A review
1University of Iowa Carver College of Medicine, Department of Internal Medicine, Division of Hematology, Oncology, and Blood and Marrow Transplantation, 200 Hawkins Drive, Iowa City, IA 52242, United States.
Abstract:
Pre-clinical data has shown that beta adrenergic stimulation can affect the development and progression of many types of cancer. The use of beta blockers as an anti-neoplastic therapy has been studied in retrospective trials and observational trials, but no definitive conclusions about efficacy have been made. Within the realm of breast cancer, significant advances in therapy have led to improved survival outcomes, yet there is room for improvement. Beta adrenergic blockade may prove an effective adjunct to standard breast cancer therapy, with little associated toxicity. This article provides a review of the published literature on beta blockade as an adjunctive cancer therapy, with a focus on breast cancer.
Insights
Beta blockers may help treat cancer. Research reviews beta adrenergic blockade as an adjunctive cancer therapy, particularly for breast cancer, showing potential benefits with low toxicity.
Area of Science:
- Oncology
- Pharmacology
Background:
- Beta adrenergic stimulation influences cancer development and progression.
- Beta blockers have been investigated for anti-neoplastic effects with inconclusive results.
- Breast cancer therapies have advanced, but further improvements are needed.
Purpose of the Study:
- To review the literature on beta blockade as an adjunctive cancer therapy.
- To focus on the role of beta blockers in breast cancer treatment.
Main Methods:
- Review of published literature.
- Analysis of pre-clinical data.
- Examination of retrospective and observational trials.
Main Results:
- Pre-clinical evidence suggests beta adrenergic stimulation impacts cancer.
- Clinical trial data on beta blockers for cancer efficacy is not definitive.
- Beta blockade shows potential as a low-toxicity adjunct for breast cancer therapy.
Conclusions:
- Beta adrenergic blockade may serve as an effective addition to standard breast cancer treatments.
- Further research is warranted to confirm the efficacy of beta blockers in oncology.
- The potential for minimal toxicity makes beta blockers an attractive area for breast cancer research.
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Neuromuscular Junction And Blockade
Targeted Cancer Therapies
There are several types of targeted therapies against...
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview

